Incorrect assumption? Mate the drug class over multiple peptides have shown 40-50 percent efficacy in pre clinical studies but have not worked on the human brain in phase 3. So you’re telling me 20 percent greater efficacy is going to create a chance to work when the others didn’t show anything. Drug class doesn’t work in the human brain and that’s a correct assumption based off other drugs in the same class, with same side effects, similar efficacy and similar structures. Anyone in pharmacology will tell you this.
AGN just got lucky it listed in 2021 before phase 3 completion in 2022 and 2023 where AGN started to not mention these other drugs and make comparisons to them anymore. Why? Ask the CEO that
AGN Media thread, page-216
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.3¢ |
Change
0.023(2.88%) |
Mkt cap ! $102.0M | |||
| Open | High | Low | Value | Volume |
| 80.0¢ | 80.3¢ | 77.0¢ | $95.33K | 121.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8967 | 78.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 639 | 1 |
View Market Depth
| Last trade - 15.38pm 28/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |